Related references
Note: Only part of the references are listed.Synthesis of [13C6]-ibrutinib
Michal Kriegelstein et al.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (2021)
Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on
Stefano Molica et al.
HEMATOLOGICAL ONCOLOGY (2020)
Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring
Dora Koller et al.
TALANTA (2020)
Signal Drift in Liquid Chromatography Tandem Mass Spectrometry and Its Internal Standard Calibration Strategy for Quantitative Analysis
Fulin Jiang et al.
ANALYTICAL CHEMISTRY (2020)
Microfiltration results in the loss of analytes and affects the in vitro genotoxicity of a complex mixture of Alternaria toxins
Georg Aichinger et al.
MYCOTOXIN RESEARCH (2020)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Bioanalysis of ibrutinib, and its dihydrodiol- and glutathione cycle metabolites by liquid chromatography-tandem mass spectrometry
J. J. M. Rood et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2018)
Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid
D. Beauvais et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2018)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Matrix effects and application of matrix effect factor
Wanlong Zhou et al.
BIOANALYSIS (2017)
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib
Varinder Kaur et al.
ANNALS OF HEMATOLOGY (2017)
Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses
Prithviraj Bose et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic study
Sridhar Veeraraghavan et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2015)
Bioanalysis of ibrutinib and its active metabolite in human plasma: selectivity issue, impact assessment and resolution
Ronald de Vries et al.
BIOANALYSIS (2015)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Internal standard response variations during incurred sample analysis by LC-MS/MS: Case by case trouble-shooting
Aimin Tan et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2009)
Matrix effects: The Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry
PJ Taylor
CLINICAL BIOCHEMISTRY (2005)
Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography/mass spectrometry: necessity or not?
E Stokvis et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2005)
High-performance liquid chromatographic-tandem mass spectrometric evaluation and determination of stable isotope labeled analogs of rofecoxib in human plasma samples from oral bioavailability studies
CM Chavez-Eng et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2002)
LC-MS-MS experiences with internal standards
J Wieling
CHROMATOGRAPHIA (2002)
Determination of pibutidine metabolites in human plasma by LC-MS/MS
K Kato et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2000)
Analyte loss due to membrane filter adsorption as determined by high-performance liquid chromatography
M Carlson et al.
JOURNAL OF CHROMATOGRAPHIC SCIENCE (2000)
Share Paper
